Testicular germ cell tumors (GCTs) remain one of the most curable solid malignancies in oncology. When diagnosed at Stage I, management is straightforward, toxicities are minimal, and long-term oncologic outcomes are excellent. Yet, these outcomes are only achievable when patients enter the healthcare system early—something that is not equitably distributed across populations.
In our county-wide audit of all GCT cases diagnosed across Bexar County from 2012–2023, we sought to look beyond traditional demographic variables of socioeconomic status (SES) and instead examine the cumulative effect of socioeconomic ‘hardship’—captured using a validated Hardship Index (HI)—on stage at diagnosis, treatment delays, progression-free survival (PFS), and overall survival (OS). Unlike typical SES metrics that focus only on income or insurance status, the HI integrates poverty, unemployment, education, dependency ratios, household crowding, and income measures. This multidimensional approach reflects the real ‘lived experience’ in which our patients seek (or struggle to seek) care.
Key Insights From Our Study
- Across 297 patients meeting inclusion criteria, we found that race and ethnicity alone did not predict stage of disease, but socioeconomic hardship did—and strongly so.
- Each unit of greater hardship increased the odds of late-stage diagnosis by 2% (p=0.002).
- Patients living in high-hardship regions were nearly twice as likely to present at Stage II–III.
- Insurance status carried independent prognostic weight: the uninsured were over twice as likely to present with advanced disease (OR 2.30).
- Geographic access mattered: each additional mile from the cancer center increased the odds of late-stage diagnosis by 7%.
- Treatment delays (time from presentation to the health care system to radical orchiectomy) were substantial—median 83 days for uninsured patients vs 40 days for insured (p=0.034).
- Progression: Patients in high-hardship areas had a fourfold increased risk of progression (HR 4.10).
- PFS disparities were driven almost entirely by NSGCT patients, whereas seminoma outcomes were similar regardless of hardship.
Why This Matters in Testicular Cancer
The toxicity of delayed diagnosis in GCTs is profound. A man with early-stage seminoma may avoid chemotherapy entirely if diagnosed promptly. Conversely, someone presenting months later with bulky NSGCT may require multi-agent cisplatin-based therapy, post-chemotherapy Retroperitoneal Lymph Node Dissection (RPLND), and years of survivorship monitoring—exposing him to cardiovascular disease, metabolic syndrome, neuropathy, and secondary malignancies.
The young men most affected often sit at the intersection of economic disadvantage, limited insurance coverage, and geographic barriers. These factors compound delays at every step: recognition of symptoms, ability to access urologic care, initiation of staging workup, and timely delivery of curative therapy.
Our findings mirror and extend national trends showing that SES—not biology—is increasingly driving the gap in outcomes for testicular cancer. In regions like South Texas, where the population is predominantly Hispanic and socioeconomic inequality is marked, these disparities widen further.
What Our Data Suggests for Clinical Practice and Policy
In a world where billions of dollars are spent on cancer research, diagnostics, and therapeutics, interventions geared to early detection and removal of barriers may ultimately have the greatest impact in improving overall survival and reducing toxicity. In testicular cancer, where survival can approach 99% with timely care, the persistence of disparities driven by hardship is both striking and unacceptable. Our study highlights that systematic barriers have a greater impact than tumor biology. To reduce avoidable morbidity and mortality in this highly curable disease, we believe efforts should shift toward:
- Early-detection pathways targeted toward high-hardship communities (increasing awareness campaigns, reducing embarrassment with the diagnosis).
- Creative means for insurance expansion and navigation programs, particularly for young adults newly diagnosed with cancer.
- Geographic access solutions, including mobile clinics, satellite survivorship services, and telemedicine
- Patient navigation and bilingual support services to address health literacy and system complexity
- Public health measures that emphasize testicular cancer awareness in schools, athletic programs, and community centers
By using a multidimensional hardship framework, our study provides a clearer understanding of why certain men present with advanced disease and how socioeconomic disadvantage translates into worse oncologic outcomes. In order to drive greater impacts in GCTs, efforts should be directed at addressing these barriers.
Written by: Deepak K. Pruthi, M.D, FRCSC, MSCI-TS, Associate Professor & Vice Chair, Department of Urology, Chief, Division of Urological Oncology, Henry B. and Edna Smith Dielmann Memorial Chair in Urologic Science, Medical Director, Urology, Mays Cancer Center/MD Anderson Cancer Center, UT Health San Antonio, San Antonio, TX
Read the Abstract